Abbott Vascular - Global Leader in Coronary and Peripheral Vascular Intervention

Company Overview (Updated April 2026)

Abbott Vascular is the coronary and peripheral vascular intervention division of Abbott Laboratories (NYSE: ABT), headquartered in Santa Clara, California, USA. As one of four core cardiovascular businesses within Abbott's Medical Devices segment (alongside Structural Heart, Electrophysiology, and Heart Failure), Abbott Vascular delivers a comprehensive suite of technologies for treating coronary artery disease (CAD) and peripheral artery disease (PAD). The division serves physicians and patients in more than 160 countries through Abbott's global commercial and manufacturing infrastructure.

Corporate Integration:

- Parent Company: Abbott Laboratories (NYSE: ABT), global healthcare leader with $44.33 billion in 2025 sales

- Business Segment: Medical Devices - Vascular (2025 sales: $2.995 billion)

- Headquarters: Santa Clara, California, USA (Vascular division)

- Manufacturing: Part of Abbott's 90+ global manufacturing sites

Historical Evolution:

- 2017: Abbott acquired St. Jude Medical for ~$23.6 billion, dramatically expanding cardiovascular capabilities

- 2017: Divested Angio-Seal and Femoseal vascular closure businesses to Terumo Corporation for ~$1.12 billion

- 2021: Acquired Walk Vascular, adding peripheral thrombectomy systems

- April 2023: Acquired Cardiovascular Systems, Inc. (CSI) for ~$890 million, adding Diamondback 360 orbital atherectomy technology

- 2024: Launched XIENCE Sierra in India; XIENCE 90 study demonstrated safety with shorter DAPT duration

- March 2026: Launched Xience Skypoint in India with enhanced size matrix for large vessel treatment

Financial Performance (2024-2025)

Vascular Division Sales (Updated 2025)

2025 Full Year:

- Worldwide Sales: $2.995 billion (reported growth +5.6%; organic growth +5.1%)

- U.S. Sales: $1.118 billion (+5.8% reported, +5.2% organic)

- International Sales: $1.877 billion (+5.4% reported, +4.9% organic)

Q4 2025 Performance:

- Worldwide Sales: $783 million (+8.0% reported, +6.5% organic)

- U.S. Sales: $288 million (+7.1%)

- International Sales: $495 million (+8.5%)

Context within Abbott Medical Devices:

- Medical Devices total 2025: $21.4+ billion

- Vascular represents ~14% of Medical Devices segment revenue

- Growth driven by coronary DES, imaging, and peripheral interventions

- CSI acquisition continued to contribute to atherectomy growth

2024 Baseline Comparison

- 2024 Worldwide Sales: $2.837 billion (+5.8%)

- 2024 U.S. Sales: $1.056 billion (+8.0%)

- 2024 International Sales: $1.781 billion (+4.6%)

Core Product Portfolio

Coronary Intervention

XIENCE Drug-Eluting Stent (DES) Family:

- XIENCE Sierra: Everolimus-eluting coronary stent system, launched in India (May 2024) and global markets

- Xience Skypoint: Next-generation DES launched in India (March 2026) with enhanced deliverability and broadest size matrix including 4.5mm and 5.0mm diameters for vessels up to 5.25mm

- XIENCE 90 Study: Demonstrated superior safety with shorter dual antiplatelet therapy (DAPT) duration, reducing bleeding risks

Coronary Balloons & Accessories:

- PTCA balloon catheters (compliant, semi-compliant, non-compliant) for pre-dilation and post-dilation

- Specialty balloons for complex lesion treatment

- Guidewires, guiding catheters, micro-catheters, and extension guide catheters

Vascular Imaging (OCT & IVUS)

Optical Coherence Tomography (OCT):

- Abbott faces no direct competition in the coronary OCT segment in the U.S.

- High-resolution intravascular imaging for plaque morphology assessment and stent optimization

Intravascular Ultrasound (IVUS):

- IVUS catheters and consoles for coronary and peripheral applications

- Supports imaging-driven PCI strategies and calcium assessment

Atherectomy & Calcium Modification

Diamondback 360 Orbital Atherectomy (Acquired via CSI):

- Handheld, catheter-based system with diamond-coated crown orbiting 360 degrees within the artery

- Treats both coronary and peripheral calcified lesions

- ECLIPSE Trial (October 2024): Evaluated Diamondback 360 for severely calcified coronary lesions; results showed orbital atherectomy plus balloon angioplasty did not achieve superior minimum stent area compared to balloon alone in the overall studied population, emphasizing the critical importance of patient selection and advanced imaging guidance for appropriate case identification

- Clinical benefit remains in truly uncrossAble or refractory calcified lesions

Peripheral Vascular Solutions

Peripheral Stents & Balloons:

- Self-expanding and balloon-expandable peripheral stents

- Drug-coated balloons (DCB) and plain balloon angioplasty for PAD

Thrombectomy Systems:

- Peripheral thrombectomy systems (via Walk Vascular acquisition, 2021)

Embolic Protection:

- Embolic protection devices (EPD) for debris capture during interventions

2024-2026 Clinical & Regulatory Milestones

Drug-Eluting Stent Advances

XIENCE Sierra Global Expansion (May 2024):

- Launched in India, one of the world's largest stent markets

- Designed for complex cases with best-in-class deliverability

XIENCE 90 Post-Market Study (November 2024):

- Positive long-term results demonstrated superior safety with shorter DAPT duration

- Enhances patient compliance and reduces bleeding risks

Xience Skypoint India Launch (March 2026):

- Next-generation DES with broadest size matrix including 4.5mm and 5.0mm diameters

- Only DES approved for vessels up to 5.25mm diameter

- Enhanced deliverability for complex PCI and tortuous anatomies

- Launched by Tushar Sharma, General Manager of Abbott's Vascular Business for India and South Asia

Atherectomy Clinical Evidence

ECLIPSE Trial Results (Presented October 2024):

- Evaluated Diamondback 360 coronary orbital atherectomy vs. conventional balloon angioplasty prior to stenting

- Primary endpoint: Minimum stent area measured by intravascular ultrasound

- Results showed no significant difference in the overall studied population, highlighting the importance of careful patient selection

- Orbital atherectomy remains valuable in specific calcified lesions that are uncrossable or refractory to conventional approaches

Market Position & Competitive Landscape

Global Ranking

U.S. Interventional Cardiology Device Market:

- #2 overall market position (behind Boston Scientific)

- Monopolistic position in OCT: No direct competition in coronary OCT segment

- Strong competitive advantage through portfolio depth and imaging-guided PCI integration

Key Competitors:

- Boston Scientific: Market leader in coronary stents; acquired Bolt Medical (IVL) for $664M (January 2025)

- Medtronic: Resolute Onyx DES, HawkOne/TurboHawk atherectomy

- Johnson & Johnson (Shockwave Medical): Dominant IVL player after $13.1B acquisition of Shockwave (2024)

- Biotronik: Orsiro Mission DES with biodegradable polymer

- Terumo: Ultimaster Tansei DES; acquired Abbott's Angio-Seal vascular closure business (2017)

- MicroPort Scientific: Firesorb bioresorbable stent (China-approved)

Market Trends (2025-2026)

- Imaging-Driven PCI: IVUS and OCT transitioning from optional to routine procedural guidance

- Calcium Modification: IVL emerging as fastest-growing segment within atherectomy; projected $2+ billion by 2034

- Complex PCI: Growing demand for devices treating calcified lesions and multivessel disease

- Shorter DAPT Protocols: XIENCE 90 data supporting reduced antiplatelet therapy duration

- Large Vessel Treatment: Xience Skypoint addresses unmet need in 4.5-5.25mm vessel diameters

Strategic Direction & 2026 Outlook

Growth Drivers

DES Portfolio Expansion:

- Xience Skypoint global expansion beyond India (2026)

- Continued leverage of XIENCE 90 shorter-DAPT clinical data

OCT Imaging Leadership:

- Maintain dominant position in coronary OCT with no direct U.S. competitor

- Expand integration of imaging into routine PCI workflows

Peripheral Vascular Growth:

- Expand Diamondback 360 utilization in appropriate calcified PAD and CAD cases

- Leverage CSI acquisition synergies and physician training programs

Operational Excellence:

- Continue gross margin expansion within Abbott's Medical Devices segment

- Benefit from Abbott's global manufacturing scale

Leadership & Corporate Information

Key Executives

Abbott Chairman & CEO: Robert B. Ford - Oversees global strategy including Vascular division

Division Leadership: Vascular business operates under Abbott's Medical Devices segment leadership

Regional Leadership: Tushar Sharma - General Manager, Vascular Business, India and South Asia (led Xience Skypoint 2026 launch)

Company Profile Summary

Division Name: Abbott Vascular

Parent Company: Abbott Laboratories (NYSE: ABT)

Headquarters: Santa Clara, California, USA

Industry: Interventional Cardiology / Peripheral Vascular Devices

2025 Revenue: $2.995 billion (+5.6% reported, +5.1% organic)

Global Ranking: #2 in interventional cardiology devices; #1 in coronary OCT

Key Acquisitions: St. Jude Medical (2017, ~$23.6B); Cardiovascular Systems, Inc. (2023, ~$890M); Walk Vascular (2021)

Contact Information

Abbott Vascular

Division Headquarters: Santa Clara, California, USA
   Corporate Headquarters: 100 Abbott Park Road, Abbott Park, IL 60064, USA
   Phone: +1-224-667-6100
   Website: www.abbott.com
   Investor Relations: www.abbottinvestor.com

Investor Information (Parent Company)

Stock Ticker: ABT (NYSE)
   2025 Group Revenue: $44.33 billion
   Medical Devices Segment: $21.4+ billion (2025)
   Vascular Division: $2.995 billion (2025)
   Global Employees: 114,000 (Abbott worldwide)

Keywords: Abbott Vascular, XIENCE, XIENCE Skypoint, XIENCE Sierra, drug-eluting stent, coronary stent, peripheral artery disease, PAD, atherectomy, Diamondback 360, CSI, Cardiovascular Systems, ECLIPSE trial, OCT, optical coherence tomography, IVUS, interventional cardiology, coronary balloon, Santa Clara, Robert Ford, Tushar Sharma, $2.995 billion, 2025 earnings